MANKIND - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 3.6
| Stock Code | MANKIND | Market Cap | 89,131 Cr. | Current Price | 2,163 ₹ | High / Low | 2,727 ₹ |
| Stock P/E | 53.5 | Book Value | 376 ₹ | Dividend Yield | 0.05 % | ROCE | 15.0 % |
| ROE | 13.9 % | Face Value | 1.00 ₹ | DMA 50 | 2,193 ₹ | DMA 200 | 2,340 ₹ |
| Chg in FII Hold | -1.49 % | Chg in DII Hold | 1.35 % | PAT Qtr | 459 Cr. | PAT Prev Qtr | 413 Cr. |
| RSI | 51.0 | MACD | -25.8 | Volume | 7,92,794 | Avg Vol 1Wk | 4,41,417 |
| Low price | 2,047 ₹ | High price | 2,727 ₹ | PEG Ratio | 6.36 | Debt to equity | 0.47 |
| 52w Index | 17.0 % | Qtr Profit Var | -25.2 % | EPS | 40.4 ₹ | Industry PE | 29.2 |
📊 Analysis: Mankind Pharma is trading at 2,163 ₹, below both its 50 DMA (2,193 ₹) and 200 DMA (2,340 ₹), indicating short-term and medium-term weakness. RSI at 51.0 suggests neutral momentum, while MACD (-25.8) reflects bearish sentiment. Intraday volume (7.9 lakh) is higher than the weekly average (4.4 lakh), showing strong participation. Fundamentals are decent with ROE 13.9%, ROCE 15.0%, and EPS at 40.4 ₹, but high P/E (53.5 vs industry 29.2) and weak profit variation (-25.2%) limit upside for intraday trading.
💰 Optimal Buy Price (Intraday): 2,155–2,165 ₹ (near support zone).
📈 Profit-Taking Levels: 2,185 ₹ (first resistance), 2,200 ₹ (secondary resistance).
⚠️ Stop-Loss / Loss Protection: 2,145 ₹ (below intraday support).
⏱️ If Already Holding: Exit if price fails to sustain above 2,185 ₹ with volume confirmation or if RSI dips below 49 intraday. Hold for extended gains only if momentum sustains above 2,200 ₹ with strong volume recovery.
Positive
- 📈 EPS at 40.4 ₹ supports valuation strength.
- 📊 PAT growth (459 Cr. vs 413 Cr.) shows sequential improvement.
- 📉 DII holdings increased (+1.35%).
- 📈 Strong intraday volume compared to weekly average.
Limitation
- ⚠️ Current price below both 50 DMA and 200 DMA.
- 📉 MACD (-25.8) indicates bearish momentum.
- 📊 High P/E (53.5) vs industry average (29.2).
- 📉 PEG ratio at 6.36 suggests expensive growth valuation.
Company Negative News
- 📉 FII holdings decreased (-1.49%).
- ⚠️ Quarterly profit variation (-25.2%) shows declining momentum.
Company Positive News
- 📈 Sequential PAT growth supports investor sentiment.
- 📊 DII accumulation (+1.35%) adds stability.
Industry
- 🏭 Pharma sector PE at 29.2, Mankind trades at a premium (53.5).
- 📈 Sector supported by defensive demand and healthcare expansion.
Conclusion
⚖️ Mankind Pharma is a moderate intraday candidate. Buy near 2,155–2,165 ₹ with stop-loss at 2,145 ₹. Profit booking can be considered at 2,185–2,200 ₹. Momentum indicators suggest caution, as MACD remains bearish despite strong volume. Traders should rely on volume confirmation before holding beyond 2,200 ₹.
Would you like me to also prepare a peer benchmarking overlay comparing Mankind Pharma with Sun Pharma, Cipla, and Dr. Reddy’s to highlight relative intraday strength in the pharma sector?